Sanara MedTech - SMTI Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sanara MedTech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SMTI shares.
View SMTI analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued twelve-month price targets for Sanara MedTech's shares. Their SMTI share price forecasts range from $50.00 to $50.00. On average, they expect the company's share price to reach $50.00 in the next twelve months. This suggests a possible upside of 24.7% from the stock's current price.
View analysts price targets for SMTI or view top-rated stocks among Wall Street analysts.

Sanara MedTech's stock was trading at $45.50 on January 1st, 2023. Since then, SMTI shares have decreased by 11.9% and is now trading at $40.10.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our SMTI earnings forecast.

Sanara MedTech Inc. (NASDAQ:SMTI) posted its quarterly earnings results on Monday, March, 20th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.04. The firm had revenue of $15.32 million for the quarter. Sanara MedTech had a negative net margin of 30.33% and a negative trailing twelve-month return on equity of 32.84%. During the same period last year, the firm posted ($0.48) earnings per share.

Sanara MedTech updated its fourth quarter 2022 earnings guidance on Wednesday, February, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $15.30 million-$15.30 million, compared to the consensus revenue estimate of $14.80 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanara MedTech investors own include Lakeland Industries (LAKE), Ovintiv (OVV), SIG (SHI), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), American Airlines Group (AAL), Abbott Laboratories (ABT), Aurora Cannabis (ACB), AC Immune (ACIU) and Applied Genetic Technologies (AGTC).

Sanara MedTech trades on the NASDAQ under the ticker symbol "SMTI."

Sanara MedTech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.34%), Susquehanna International Group LLP (0.18%), Bamco Inc. NY (0.13%), Citigroup Inc. (0.11%), Millennium Management LLC (0.10%) and Price T Rowe Associates Inc. MD (0.07%). Insiders that own company stock include Shawn M Bowman and Zachary B Fleming.
View institutional ownership trends.

Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SMTI stock can currently be purchased for approximately $40.10.

Sanara MedTech (NASDAQ:SMTI) has a market capitalization of $332.83 million and generates $24.14 million in revenue each year. The company earns $-7,920,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

Sanara MedTech's mailing address is 1200 Summit Avenue Suite 414, Fort Worth TX, 76102. The official website for the company is www.wndm.com. The company can be reached via phone at (817) 529-2300 or via email at ir@sanaramedtech.com.